Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Niacin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Niacin. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005710-12 Sponsor Protocol Number: Ep_Li 001_2006 Start Date*: 2007-09-28
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study)
    Medical condition: Lipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated L...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005093-70 Sponsor Protocol Number: 0524A-020 Start Date*: 2005-12-29
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercho...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020603 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) AT (Completed) DE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017622-39 Sponsor Protocol Number: ERNLPT01 Start Date*: 2010-04-21
    Sponsor Name:Clinical Center Ljubljana
    Full Title: A double blind, randomized study to compare influence of niacin/laropiprant on functional and morphological characteristics of arterial wall and parameters of inflammation in subjects with CHD alre...
    Medical condition: To evaluate the influence of 12 weeks of ER niacin/laropiprant therapy on endothelial dependent dilatation of the arterial wall in CHD patients already treated with a statin compared to placebo as...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003107-39 Sponsor Protocol Number: 0524A-023 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck & Co
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012772-27 Sponsor Protocol Number: 0524A-102 Start Date*: 2009-11-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (E...
    Medical condition: Dyslipidemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) DE (Completed) FR (Completed) FI (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000465-37 Sponsor Protocol Number: 0524A-082 Start Date*: 2008-05-30
    Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Ther...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001885-17 Sponsor Protocol Number: CTSUTHRIVE1 Start Date*: 2006-09-26
    Sponsor Name:University of Oxford
    Full Title: HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524.
    Medical condition: Cardiovascular disease: History of myocardial infarction; or cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation);...
    Disease: Version SOC Term Classification Code Term Level
    9.0 10051615 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002515-75 Sponsor Protocol Number: 0524-069 Start Date*: 2007-09-04
    Sponsor Name:MSD Finland Oy
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) SE (Completed) IT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002516-26 Sponsor Protocol Number: 0524-063 Start Date*: 2007-07-30
    Sponsor Name:Merck, Sharp & Dohme Ireland (Human Health) Limited
    Full Title: A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministrati...
    Medical condition: Hypercholesterolemia and Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) SE (Completed) LT (Completed) DE (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005347-25 Sponsor Protocol Number: INEF Start Date*: 2006-01-17
    Sponsor Name:Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel
    Full Title: Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo...
    Medical condition: Women or men > 35 and < 80 years of age with a documented, clinically stable coronary artery disease (CAD) and a flow-mediated vasodilatation (FMD) of less than 8% from the heart catheter register ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003093-21 Sponsor Protocol Number: 20091977 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Department I
    Full Title: Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study -
    Medical condition: Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001443-49 Sponsor Protocol Number: MK0524A-158 Start Date*: 2012-11-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents with Heterozygous Familial Hypercholesterolemia
    Medical condition: Heterozygous Familial Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    14.1 100000004850 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004218-34 Sponsor Protocol Number: NIFLO Start Date*: 2006-04-27
    Sponsor Name:Department of Cardiology, UK Aachen
    Full Title: Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins
    Medical condition: coronary artery disease and lipid disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005094-30 Sponsor Protocol Number: 0524B-022 Start Date*: 2006-01-04
    Sponsor Name:Merck & Co., Inc
    Full Title: A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or ...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020603 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001913-13 Sponsor Protocol Number: 0524A-041 Start Date*: 2006-11-29
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Art...
    Medical condition: heterozygous familial hypercholesterolemia (HeFH)
    Disease: Version SOC Term Classification Code Term Level
    9.0 10057099 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002017-39 Sponsor Protocol Number: 0524-067 Start Date*: 2007-07-11
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of St...
    Medical condition: Hypercholesterolemia or Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) FR (Completed) CZ (Completed) SE (Completed) NL (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008006-46 Sponsor Protocol Number: 0000-111 Start Date*: 2009-05-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA)
    Medical condition: carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001007-12 Sponsor Protocol Number: MK-0524B-143 Start Date*: 2011-07-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Pati...
    Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015729-35 Sponsor Protocol Number: PCOS&Niacin Start Date*: 2009-11-23
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS)
    Medical condition: Polycystic ovary syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019954-42 Sponsor Protocol Number: KP-Niacin-2010 Start Date*: 2010-10-26
    Sponsor Name:Med. Klinik II, Klinikum der Universität München Grosshadern
    Full Title: Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia
    Medical condition: Dyslipoproteinemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063903 Dyslipoproteinemia LLT
    12.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:21:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA